Drug intelligence / Profile preview

Nvzhen Granule

Development stage: Unknown
Lead developer: PegBio
Administration: Oral

Overview

Nvzhen Granule is a Traditional Chinese Medicine (TCM) product developed by Shandong Phoenix Pharmaceutical for the treatment of chronic insomnia. It is specifically formulated for patients presenting with the TCM pattern of liver–kidney yin deficiency and hyperactivity of heart–liver fire. The formulation typically contains extracts from botanical sources such as *Ligustrum lucidum* (Nvzhenzi), which is traditionally used in Chinese medicine to nourish the liver and kidneys. Nvzhen Granule is currently being evaluated in Phase II clinical trials in China to assess its efficacy on subjective sleep quality and objective polysomnographic (PSG) parameters, as well as its impact on traditional TCM symptom scores over an 8-week treatment period.

Brand names: Nvzhen Granule
Other names: Nvzhen女贞颗粒

Beyond the preview

Go deeper on Nvzhen Granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nvzhen Granule.

Explore the full profile